Rheumatologische Schwerpunktpraxis — Clinical Trial Site

24 Registered trials

7 Currently recruiting

Organisation

Rheumatologische Schwerpunktpraxis

Location

Berlin, Germany

Identifier

ORG-100043165

Address

Bundesallee 104-105, Friedenau, 12161, Germany

Departments

#305
#40025
#40025: nap
#40025: Rheumatologische Schwerpunktpraxis
1002: Rheumatologische Schwerpunktpraxis
Innere Medizin und Rheumatologie
N/A
NA
Rheumapraxis Steglitz
Rheumathologiesche Schwerpunktpraxis
Rheumatologische Schwerpunktpraxis
Rheumatologische Schwerpunktpraxis
Rheumatologische Schwerpunktpraxis im Ärztehaus am Walter-Schreiber-Platz
Rheumatology

Clinical trials at this site (24)

Search interface

A study to investigate how well and safe a trial drug called AZD1163, administered as an injection, works in improving symptoms and inflamma… Pending

2025-522076-85-00 Rheumatoid arthritis 4
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P… Pending

2025-522471-28-00 psoriatic arthritis (PsA) 5
A Phase 3, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib in Subjects with Active Pso… Pending

2025-522586-30-00 Psoriatic Arthritis 5
A clinical study of tulisokibart in people with psoriatic arthritis (MK-7240-015) Recruiting

2025-520997-21-00 Psoriatic arthritis 4 2026-05-08
A study to learn if bimekizumab given in different ways is safe and moves similarly throughout the body over time in adults Recruiting

2025-522782-30-00 CCI 3 2026-04-07
A study to learn about the effectiveness and safety of different doses of JNJ-88545223 in people with active psoriatic arthritis Recruiting

2025-523141-10-00 Active Psoriatic Arthritis 4 2026-03-20
A clinical study of tulisokibart to treat radiographic axial spondyloarthritis (MK-7240-013) Recruiting

2025-521059-21-00 Radiographic axial spondyloarthritis (as known as ankyl 4 2025-11-25
A clinical study of tulisokibart in people with rheumatoid arthritis (MK-7240-014) Recruiting

2025-521745-25-00 Rheumatoid Arthritis 4 2025-11-06
A Study of Zasocitinib in Adults with Psoriatic Arthritis Who Have Not Taken Biologic Medicines Recruiting

2024-513111-27-00 Psoriatic Arthritis 5 2025-06-26
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo and risankizumab (active reference arm) in partici… Recruiting

2024-516219-25-00 psoriatic arthritis 5 2025-03-25
Proof of Concept trial with CIT-013 in Rheumatoid Arthritis Ended

2024-517356-35-00 Moderately Active Rheumatoid Arthritis 4 2025-07-29
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active… Ended

2024-516213-20-00 Psoriatic arthritis 5 2025-03-25
A study to learn how well bimekizumab works and how safe it is in adults with psoriatic arthritis Ended

2024-511738-11-00 Psoriatic arthritis 5 2024-12-18
An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients with Psoriatic Arthritis. Ended

2022-501480-41-00 Psoriatic Arthritis 5 2023-04-06
A multicenter study of secukinumab, with a randomized double-blind, placebo-controlled withdrawal-retreatment period, to evaluate maintenanc… Ended

2023-509320-17-00 non-radiographic axial spondyloarthritis 6 2023-03-28
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to… Ended

2023-504564-42-00 Moderate to Severe Rheumatoid Arthritis 4 2024-04-08
A study to evaluate SAR441566 efficacy and safety in adults with rheumatoid arthritis Ended

2023-503910-60-00 Rheumatoid arthritis 4 2024-03-05
A study to test if izokibep improves psoriatic arthritis symptoms and to see how safe izokibep is Ended

2022-501362-22-00 Psoriatic Arthritis 10 2023-04-18
Efficacy and Safety of secukinumab in patients with new onset of giant cell arteritis who are in clinical remission Ended

2024-512856-40-00 Giant Cell Arteritis 5 2022-09-21
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Naive Su… Ended

2024-512142-42-00 Psoriatic Arthritis 5 2021-10-05
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experien… Ended

2023-507415-35-00 Psoriatic Arthritis 5 2021-01-15
An extension study to learn if Bimekizumab works and is safe over a long period in adults with Active Axial Spondyloarthritis. Ended

2023-506527-28-00 Axial Spondyloarthritis 5 2020-06-29
Evaluation of upadacitinib in adult subjects with axial spondyloarthritis Ended

2022-501018-78-00 Axial Spondyloarthritis 5 2020-03-23
A study to learn if Bimekizumab is safe and works over a long period in adults with Active Psoriatic Arthritis Ended

2023-506528-95-00 Psoriatic Arthritis 5 2019-11-21